WE CLAIM:

1. A compound of formula I:



I;

wherein:

m, q and r are independently 0, 1 or 2;

n is 0 or 1;

R is H or COR^2;

R^0 is independently at each occurrence OH, CF_3, halo, C_1-C_6 alkyl or C_1-C_6 alkoxy;

R^1 and $R^{1'}$ are independently C_1-C_6 alkyl, C_1-C_6 alkoxy, NR^3R^{3a}, CF_3 or CH_2CF_3; or when n and q are 0, the $-SO_2R^1$ moiety may combine with the phenyl ring to which it is attached to form a moiety of formula (a) or (b):



(a) (b);

wherein t and v are 0, 1 or 2 provided that the sum of t + v must be 2;

R^2 is C_1-C_6 alkyl; C_1-C_6 alkoxy; NR^4R^4; phenoxy; or phenyl optionally substituted with halo;

R^3 is C_1-C_6 alkyl or phenyl;

R^{3a} and R^4 are independently at each occurrence H, C_1-C_6 alkyl, or phenyl;

X is O, CH_2 or CO;

X^1 is O or NR^5;

R^5 is H or C_1-C_6 alkyl; and

R^8 is H or methyl provided that if r is 1 or 2, then R^8 must be H and that if r is 0, then R^8 must be methyl; and

Y is S, CH_2CH_2 or CH=CH; or a pharmaceutical acid addition salt thereof.

2. The compound of claim 1 wherein m is 2; and r is 1 or 2; or a pharmaceutical acid addition salt thereof.

3. The compound of claim 1 or 2 wherein R^2 is C_1-C_6 alkyl, $NHCH_3$ or phenyl and the $-SO_2R^1$ moiety does not combine with the phenyl ring to which it is attached to form a moiety of formula (a) or (b); or a pharmaceutical acid addition salt thereof.

4. The compound of any one of claims 1-3 wherein n is 0; q is 0 or 1; the $-SO_2R^1$ moiety is at the para-position of the phenyl ring to which it is attached; R^0 is OH, CF_3, fluoro, chloro, methyl or ethyl; R^1 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl or CF_3; R^2 is C_1-C_6 alkyl or phenyl; and Y is S or CH=CH; or a pharmaceutical acid addition salt thereof.

5. The compound of any one of claim 1-4 wherein X and X^1 are O; or a pharmaceutical acid addition salt thereof.

6. The compound of any one of claims 1-5 wherein q is 0; R^1 is methyl, ethyl, cyclopropyl or CF_3; and Y is CH=CH; or a pharmaceutical acid addition salt thereof.

7. The compound of any one of claims 1-6 selected from the group consisting of:








;

or a pharmaceutical acid addition salt thereof.

8. The compound which is:



;

or a pharmaceutical acid addition salt thereof.

9. The compound which is:



;

or a pharmaceutical acid addition salt thereof.

10. The compound which is:



;

or a pharmaceutical acid addition salt thereof.

11. The compound which is:



;

or a pharmaceutical acid addition salt thereof.

12. The compound which is:



;

or a pharmaceutical acid addition salt thereof.

13. The compound which is:



;

or a pharmaceutical acid addition salt thereof.

14. The compound of any one of claims 1-13 which is the hydrochloride salt.

15. A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of any one of claims 1-14, or a pharmaceutical acid addition salt thereof.

16. A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of any one of claims 1-14, or a pharmaceutical acid addition salt thereof.

17. A compound of any one of claims 1-14, or a pharmaceutical acid addition salt thereof, for use in treating endometriosis and/or uterine leiomyoma.

18. A compound of formula II:



II;

wherein:

m, q, r and u are independently 0, 1 or 2;

n is 0 or 1;

R^0 is independently at each occurrence OH, CF_3, halo, C_1-C_6 alkyl or C_1-C_6 alkoxy;

R^1 and $R^{1'}$ are independently C_1-C_6 alkyl, C_1-C_6 alkoxy, NR^3R^{3a}, CF_3 or CH_2CF_3; or when n and q are 0, the $-SO_uR^1$ moiety may combine with the phenyl ring to which it is attached to form a moiety of formula (c) or (d):



(c) (d);

wherein t and v are 0, 1 or 2 provided that the sum of t + v must be 2;

R^2 is C_1-C_6 alkyl; C_1-C_6 alkoxy; NR^4R^4; phenoxy; or phenyl optionally substituted with halo;

R^3 is C_1-C_6 alkyl or phenyl;

R^{3a} and R^4 are independently at each occurrence H, C_1-C_6 alkyl or phenyl;

R^6 is H, C_1-C_6 alkyl, benzyl or COR^2;

R^7 is H, C_1-C_6 alkyl or CO_2(C_1-C_6 alkyl);

R^8 is H or methyl provided that if r is 1 or 2, then R^8 must be H and that if r is 0, then R^8 must be methyl;

X is O, CH_2 or CO;

X^2 is O or NR^7;

Y is S, CH_2CH_2 or CH=CH; or a pharmaceutical acid addition salt thereof; provided that u can only be 2 when R^6 is C_1-C_6 alkyl or benzyl; or an acid addition salt thereof; and further provided that the compound of formula II is not:



or



19. The compound of claim 18, or an acid addition salt thereof, wherein r is 1 or 2; and

a) if n is 0 and the SO_uR^1 moiety and R^0 combine with the phenyl ring to which they are both attached to form a moiety of formula (c) or (d), then u is 2; and

b) if n is 1, then m and u are both 0, are both 1 or are both 2.

20. The compound of claim 18 or 19 wherein the -SO_uR^1 moiety does not combine with the phenyl ring to which it is attached to form a moiety of formula (c) or (d) and is at the para-position of said phenyl ring to which it is attached; n is 0; q is 0 or 1;

R^0 is OH, CF_3, fluoro, chloro, methyl or ethyl; R^1 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl or CF_3; R^2 is C_1-C_6 alkyl or phenyl; X and X^1 are O; and Y is S or CH=CH; or an acid addition salt thereof.

21. The compound of any one of claims 18-20 wherein q is 0; R^1 is methyl, ethyl, cyclopropyl or CF_3; and Y is CH=CH; or an acid addition salt thereof.

22. The compound of any one of claims 18-21 selected from the group consisting of:









;

or an acid addition salt thereof.